Illumina, Inc. (NASDAQ: ILMN) and MyOme, a leading genomics innovation and risk modeling company, today announced a collaboration and investment by Illumina into MyOme. The collaboration and investmen ...

Recent industry reports have highlighted past and projected rapid expansion in the DNA diagnostics and genomics markets, driven by liquid biopsies, direct-to-consumer testing, and personalized ...

San Diego gene sequencing giant Illumina is investing more in artificial intelligence to fuel the company’s growth strategy through a partnership with Nvidia. Nvidia — the Santa Clara tech company at ...

Illumina is welcoming a new addition to its DNA sequencing lineup, with a pair of accessible benchtop instruments that incorporate the tech and chemistry used by its largest, top-of-the-line machines.

Illumina’s announced partnerships with IBM’s Watson and Philips help shore up the firm's data-analysis capabilities and clinical diagnostic marketing efforts, respectively, but the announcement of a ...

Illumina remains by far the leader in the NGS sequencing market. After the divestment of Grail, Illumina's core business could become highly cash-generative again with close to 30% FCF margin to ...

Illumina, the market leader in DNA sequencing equipment, said Monday that it has begun layoffs and will reduce its San Diego real estate footprint as part of an effort to slash annual expenses by $100 ...

Recent advancements in next-generation sequencing have led to substantial increases in throughput, coupled with reduced expenses. Due to these improvements, the process of library preparation has ...

Aug 13 (Reuters) - Illumina (ILMN.O), opens new tab said on Tuesday it has partnered with the Broad Institute to develop new kits that will allow large-scale gene ...

Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO ...